Lucas V.A. Boersma
A5078586706- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiomyopathy and Myosin Studies
- Cardiac Imaging and Diagnostics
- Cardiac Structural Anomalies and Repair
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Neurological disorders and treatments
- Cardiac tumors and thrombi
- Cardiovascular Effects of Exercise
- Cardiovascular Function and Risk Factors
- Neuroscience and Neural Engineering
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Syncope and Autonomic Disorders
- Advanced MRI Techniques and Applications
- Cardiac Valve Diseases and Treatments
- ECG Monitoring and Analysis
- Heart Rate Variability and Autonomic Control
- Acute Ischemic Stroke Management
- Peripheral Artery Disease Management
- Cardiac Arrest and Resuscitation
- Cardiac Fibrosis and Remodeling
- Ion channel regulation and function
Amsterdam University Medical Centers
2018-2025
St. Antonius Ziekenhuis
2016-2025
University of Amsterdam
2018-2025
Agaplesion Markus Hospital
2024
Cleveland Clinic
2024
University Medical Center
2024
Amsterdam UMC Location Vrije Universiteit Amsterdam
2024
St. Eugenio Hospital
2024
ASL Roma
2024
Hôpital Maison Blanche
2024
Mortality and morbidity are higher among patients with atrial fibrillation heart failure than those alone. Catheter ablation for has been proposed as a means of improving outcomes who otherwise receiving appropriate treatment.We randomly assigned symptomatic paroxysmal or persistent did not have response to antiarrhythmic drugs, had unacceptable side effects, were unwilling take these drugs undergo either catheter (179 patients) medical therapy (rate rhythm control) (184 in addition...
Implantable cardioverter-defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate need for venous access, we designed and tested an entirely subcutaneous ICD system.First, conducted two short-term clinical trials to identify a suitable device configuration assess energy requirements. We evaluated four configurations 78 who were candidates implantation subsequently best 49 additional determine...
The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) is the first defibrillator that avoids placing electrodes in or around heart. Two large prospective studies (IDE [S-ICD System IDE Clinical Investigation] and EFFORTLESS [Boston Scientific Post Market S-ICD Registry]) have reported 6-month to 1-year data on S-ICD. objective of this study was evaluate safety efficacy a diverse population. Data from were pooled. Shocks independently adjudicated, complications measured...
Aims Left atrial appendage closure is a non-pharmacological alternative for stroke prevention in high-risk patients with non-valvular fibrillation. The objective of the multicentre EWOLUTION registry was to obtain clinical data on procedural success and complications, long-term patient outcomes, including bleeding incidence stroke/transient ischaemic attack (TIA). Here, we report peri-procedural outcomes up 30 days. Methods results Baseline/implant are available 1021 subjects. Subjects study...
The totally subcutaneous implantable-defibrillator (S-ICD) is a new alternative to the conventional transvenous ICD system minimize intravascular lead complications. There are limited data describing long-term performance of S-ICD. This paper presents first large international patient population collected as part EFFORTLESS S-ICD Registry. Registry non-randomized, standard care, multicentre designed collect long-term, system-related, clinical, and reported outcome from implanted patients...
Catheter ablation (CA) and minimally invasive surgical (SA) have become accepted therapy for antiarrhythmic drug-refractory atrial fibrillation. This study describes the first randomized clinical trial comparing their efficacy safety during a 12-month follow-up.One hundred twenty-four patients with fibrillation left dilatation hypertension (42 patients, 33%) or failed prior CA (82 67%) were to (63 patients) SA (61 patients). consisted of linear antral pulmonary vein isolation optional...
The subcutaneous implantable cardioverter-defibrillator (ICD) was designed to avoid complications related the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing these systems has been based primarily on observational studies.We conducted a noninferiority trial in which patients with indication for but no pacing were assigned receive or ICD. primary end point composite of device-related and inappropriate shocks; margin upper boundary 95% confidence interval...
The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads. global EFFORTLESS S-ICD (Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS the S-ICD) registry is collecting outcomes in 985 patients during a 5-year follow-up. primary goal determine safety by evaluating complications inappropriate shock rate. This first report on full patient cohort study endpoints with...
Pulsed field ablation uses electrical pulses to cause nonthermal irreversible electroporation and induce cardiac cell death. may have effectiveness comparable traditional catheter while preventing thermally mediated complications.The PULSED AF pivotal study (Pulsed Field Ablation Irreversibly Electroporate Tissue Treat AF) was a prospective, global, multicenter, nonrandomized, paired single-arm in which patients with paroxysmal (n=150) or persistent symptomatic atrial fibrillation (AF)...
Background— Knowledge about the incidence of cardiac arrhythmias after acute myocardial infarction has been limited by lack traditional ECG recording systems to document and confirm asymptomatic symptomatic arrhythmias. The Cardiac Arrhythmias Risk Stratification After Myocardial Infarction (CARISMA) trial was designed study prognostic significance documented an implantable monitor among patients with reduced left ventricular ejection fraction. Methods Results— A total 1393 5869 (24%)...
Ablation of persistent atrial fibrillation (AF) remains a challenge. Left fibrosis plays an important role in the pathophysiology AF and has been associated with poor procedural outcomes.To investigate efficacy adverse events targeting detected on magnetic resonance imaging (MRI) reducing arrhythmia recurrence AF.The Efficacy Delayed Enhancement-MRI-Guided Fibrosis vs Conventional Catheter Atrial Fibrillation trial was investigator-initiated, multicenter, randomized clinical involving 44...
Background: Left atrial appendage occlusion with WATCHMAN has emerged as viable alternative to vitamin K antagonists in randomized controlled trials. Evaluating real-life clinical outcomes fibrillation patients receiving the left closure technology was designed collect prospective multicenter of thromboembolic events, bleeding, and mortality for implanted a routine daily practice. Methods: One thousand twenty implant procedure were prospectively followed 47 centers. indication based on...
Permanent cardiac pacing is the only effective treatment for symptomatic bradycardia, but complications associated with conventional transvenous systems are commonly related to lead and pocket. We describe early performance of a novel self-contained miniaturized pacemaker. Patients having Class I or II indication VVI underwent implantation Micra transcatheter system, from femoral vein fixated in right ventricle using four protractible nitinol tines. Prespecified objectives were >85% freedom...
The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prevention. However, patients in previous S-ICD studies had fewer comorbidities, less left ventricular dysfunction, received more inappropriate shocks (IAS) than typical transvenous ICD trials. UNTOUCHED trial (Understanding Outcomes With the Primary Prevention Patients Low Ejection Fraction) was designed to evaluate IAS rate a typical, contemporary patient population implanted...
The extravascular implantable cardioverter–defibrillator (ICD) has a single lead implanted substernally to enable pause-prevention pacing, antitachycardia and defibrillation energy similar that of transvenous ICDs. safety efficacy ICDs are not yet known.
The first edition of Europace journal in 1999 came right around the time landmark publication electrophysiologists from Bordeaux, establishing how elimination ectopic activity pulmonary veins (PVs) resulted a marked reduction atrial fibrillation (AF). past 25 years have seen an incredible surge scientific interest to develop new catheters and energy sources optimize durability safety ablation, as well study mechanisms for AF devise ablation strategies. While beginning was performed with...
The subcutaneous implantable cardioverter-defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the ICD cannot provide bradycardia and antitachycardia pacing. Whether modular pacing-defibrillator system comprising leadless pacemaker in wireless communication to pacing safe remains unknown.
Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk stroke. Left appendage closure a mechanical alternative to anticoagulation, but data regarding its use are lacking.
Abstract A significant proportion of patients who suffer from atrial fibrillation and are in need thromboembolic protection not treated with oral anticoagulation or discontinue this treatment shortly after its initiation. This undertreatment has improved sufficiently despite the availability direct anticoagulants which associated less major bleeding than vitamin K antagonists. Multiple reasons account for this, including events ischaemic strokes whilst on anticoagulation, a serious risk...
AimsTo determine whether risk stratification tests can predict serious arrhythmic events after acute myocardial infarction (AMI) in patients with reduced left ventricular ejection fraction (LVEF ≤ 0.40).